Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT00981240 Completed - Clinical trials for Acute Myelogenous Leukemia

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

Start date: September 2009
Phase: Phase 1
Study type: Interventional

Primary objectives: - To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen - To evaluate the pharmacokinetic (PK) profile of SAR103168 Secondary objectives: - To characterize the global safety profile of SAR103168 - To evaluate preliminary anti-leukemia activity - To investigate the potential induction effect on CYP3A4 and persistence of this effect by using oral midazolam as a probe substrate in patients enrolled into the expanded cohort at the MTD - To determine the metabolic pathways of SAR103168 and identify the chemical structures of metabolites - To determine the potential impact of SAR103168 on the QTc interval in patients enrolled at the MTD

NCT ID: NCT00980018 Completed - Clinical trials for Chronic Myelogenous Leukemia

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

MACS0999
Start date: December 2009
Phase: Phase 4
Study type: Interventional

The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to nilotinib therapy.

NCT ID: NCT00978731 Completed - Leukemia Clinical Trials

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Start date: December 2005
Phase: Phase 1
Study type: Interventional

To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.

NCT ID: NCT00977782 Completed - Clinical trials for Acute Myeloid Leukemia

Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, and pharmacokinetics in AML and high risk MDS patients with either wild type or mutated FLT3 using PKC412 with intra-patient dose escalation.

NCT ID: NCT00975975 Completed - Multiple Myeloma Clinical Trials

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.

NCT ID: NCT00969891 Completed - Clinical trials for Acute Myeloid Leukemia

Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.

NCT ID: NCT00968071 Completed - Clinical trials for Myelodysplastic Syndrome

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine (decitabine) in combination with Mylotarg (gemtuzumab ozogamicin) can help to control AML or high-risk MDS. The safety of this drug combination will also be studied.

NCT ID: NCT00964873 Completed - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Start date: August 2009
Phase: Phase 1
Study type: Interventional

An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

NCT ID: NCT00962767 Completed - Clinical trials for Leukemia, Myelocytic, Acute

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.

NCT ID: NCT00957385 Completed - Clinical trials for Acute Myeloid Leukemia

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.